Patents by Inventor Steven James Harper

Steven James Harper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10301264
    Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 28, 2019
    Assignee: The University of Nottingham
    Inventors: Steven James Harper, David Owen Bates, Melissa Gammons, Jonathan Morris
  • Patent number: 9447418
    Abstract: The invention provides a method of selectively pro-oranti-angiogenic treatment of a mammalian subject, comprising site-specific control of alternative splicing during processing of VEGF pre-mRNA transcribed from the C terminal exon 8 of the VEGF gene using controlling agents for the splicing, wherein one or more controlling agent which favors proximal splice site (PSS) splicing in said processing is used in the pro-angiogenic treatment and one or more controlling agent which favors distal splice site (DSS) splicing in said processing is used in the anti-angiogenic treatment.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: September 20, 2016
    Assignee: UNIVERSITY OF BRISTOL
    Inventors: David Bates, Steven James Harper, Dawid Grzegorz Nowak
  • Publication number: 20150274668
    Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.
    Type: Application
    Filed: October 17, 2013
    Publication date: October 1, 2015
    Applicant: The University of Bristol
    Inventors: Steven James Harper, David Owen Bates, Melissa Gammons, Jonathan Morris
  • Publication number: 20130287803
    Abstract: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing neuropathic and neurodegenerative disorders, or for use as a neuroprotective or neuroregenerative agent in vivo or in vitro. The VEGFxxxb is preferably VEGF165b.
    Type: Application
    Filed: April 30, 2013
    Publication date: October 31, 2013
    Inventors: David Bates, Lucy Donaldson, Steven James Harper, Jing Hua
  • Patent number: 8530150
    Abstract: A method of detecting a risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the pregnant female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, comprises detecting the level of a VEGFxxxb in a sample from the pregnant female mammal at less than about 24 weeks of gestation and comparing the detected level with a reference level. A reduced level in the sample from the pregnant female mammal is indicative of a risk of the pregnant female mammal developing pre-eclampsia or a complication linked thereto or of the fetus developing the fetal or neonatal deficiency linked to maternal pre-eclampsia.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: September 10, 2013
    Assignee: The University of Bristol
    Inventors: David Owen Bates, Victoria Louise Bills, Steven James Harper, Yan Qiu
  • Publication number: 20120010138
    Abstract: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing microvascular hyperpermeability disorders, or in regulating the pro-angiogenic pro-permeability properties of VEGFxxx isoforms, or in supporting epithelial cell survival without increased permeability, or in reducing the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes in vivo or in vitro.
    Type: Application
    Filed: May 23, 2011
    Publication date: January 12, 2012
    Inventors: David Owen Bates, Steven James Harper, Andrew Salmon
  • Publication number: 20110076259
    Abstract: A method of detecting a risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the pregnant female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, comprises detecting the level of a VEGFxxxb in a sample from the pregnant female mammal at less than about 24 weeks of gestation and comparing the detected level with a reference level. A reduced level in the sample from the pregnant female mammal is indicative of a risk of the pregnant female mammal developing pre-eclampsia or a complication linked thereto or of the fetus developing the fetal or neonatal deficiency linked to maternal pre-eclampsia.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Inventors: David Owen Bates, Victoria Louise Bills, Steven James Harper, Yan Qiu
  • Publication number: 20110039772
    Abstract: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing neuropathic and neurodegenerative disorders, or for use as a neuroprotective or neuroregenerative agent in vivo or in vitro. The VEGFxxxb is preferably VEGF165b.
    Type: Application
    Filed: February 27, 2009
    Publication date: February 17, 2011
    Inventors: David Bates, Lucy Donaldson, Steven James Harper, Jing Hua
  • Publication number: 20100210527
    Abstract: The invention provides a method of selectively pro-oranti-angiogenic treatment of a mammalian subject, comprising site-specific control of alternative splicing during processing of VEGF pre-mRNA transcribed from the C terminal exon 8 of the VEGF gene using controlling agents for the splicing, wherein one or more controlling agent which favours proximal splice site (PSS) splicing in said processing is used in the pro-angiogenic treatment and one or more controlling agent which favours distal splice site (DSS) splicing in said processing is used in the anti-angiogenic treatment.
    Type: Application
    Filed: March 10, 2008
    Publication date: August 19, 2010
    Applicant: UNIVERSITY OF BRISTOL
    Inventors: David Bates, Steven James Harper, Dawid Grzegorz Nowak